# A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

> **NCT07020832** · PHASE3 · RECRUITING · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 320 (estimated)

## Conditions studied

- Delayed Graft Function
- End Stage Renal Disease
- Deceased Donor Kidney Transplant

## Interventions

- **DRUG:** Pegcetacoplan
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07020832
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-08
- **Final completion:** 2028-08
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020832, "A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07020832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*